

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2014

CELSION CORPORATION

(Exact name of registrant as specified in its Charter)

Delaware
(State or other jurisdiction
of incorporation)

001-15911
(Commission
File Number)

52-1256615
(IRS Employer
Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311
(Address of principal executive offices) (Zip Code)

(609) 896-9100
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition.

On August 7, 2014, Celsion Corporation issued a press release reporting its financial results for the quarter ended June 30, 2014. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On July 31, 2014, Celsion Corporation announced it would hold a conference call August 7, 2014 to discuss its second quarter 2014 financial results and provide business updates. The conference call will also be broadcast live on the internet at <http://www.celsion.com>.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Celsion Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release titled “Celsion Corporation Reports Second Quarter 2014 Financial Results” issued by Celsion Corporation on August 7, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELSION CORPORATION

Dated: August 7, 2014

By: /s/ Jeffrey W. Church

Jeffrey W. Church

Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release titled "Celsion Corporation Reports Second Quarter 2014 Financial Results" issued by Celsion Corporation August 7, 2014.



Celsion Corporation Reports Second Quarter 2014 Financial Results

Company Completes Acquisition of EGEN, Inc.

Company to Hold Conference Call Today at 11:00 a.m. EDT

LAWRENCEVILLE, N.J. – August 7, 2014 – Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014. The Company also provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy and RNA delivery.

“Our significant progress over the past quarter is consistent with our previously stated objectives and has established a new growth trajectory for Celsion. With multiple opportunities to create long-term value for our shareholders, Celsion represents a development company of unique proportions,” said Michael Tardugno, Celsion’s President and Chief Executive Officer. “With our recent acquisition of EGEN, we have created a fully-integrated oncology company with a multi-phase pipeline of chemotherapies, immunotherapies and DNA or RNA-based therapies. We are now focused on successfully executing our Phase III OPTIMA Study for ThermoDox® plus optimized radiofrequency ablation in primary liver cancer. We will also be working to leverage the potential of ThermoDox® in additional indications, and advancing development of our newest clinical asset, EGEN-001, in both ovarian cancer and glioblastoma.”

Recent Corporate Highlights

Completed Acquisition of EGEN, Inc. In June, Celsion completed its acquisition of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition included EGEN’s Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA and TheraSilence™ for delivery of RNA.

Advanced Global Regulatory Efforts in Support of the OPTIMA Study. During the second quarter, Celsion received regulatory clearance to initiate its Phase III OPTIMA Study evaluating ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer at clinical trial sites in Taiwan, Hong Kong, South Korea, Malaysia and Canada. Celsion also announced that it has filed Clinical Trial Applications in the Philippines and Thailand, as well as a request for a Voluntary Harmonization Procedure (VHP) in Europe, which provides for the assessment of multinational clinical trial applications across several European countries, including Germany, France and Spain. The OPTIMA trial is designed to enroll 550 patients at up to 100 sites in the North America, Europe, China and Asia Pacific and support registration in key liver cancer markets worldwide.

Reported Positive Updated Survival Data from the HEAT Study. In July, Celsion announced updated results from its retrospective analysis of the Company’s 701-patient HEAT Study of ThermoDox® in combination with RFA in primary liver cancer. As of June 30, 2014, the latest quarterly Overall Survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the study patients), the combination of ThermoDox® and optimized RFA provided a 57% improvement in OS compared to optimized RFA alone. The Hazard Ratio at this analysis is 0.639 (95% CI 0.419 - 0.974) with a p-value of 0.037. This data provides a strong rationale for the Company’s ongoing Phase III OPTIMA Study.

Announced Positive Interim Data from Phase 2 DIGNITY Study. In July, Celsion reported remarkable interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in combination with mild hyperthermia in refractory patients with recurrent chest wall breast cancer. Based on data available to date, 60% of 10 evaluable patients experienced a stabilization of their highly aggressive disease, with 3 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD).

Initiation of Clinical Trial Evaluating ThermoDox® Plus HIFU in Metastatic Liver Cancer. In August, a proof of concept clinical study of ThermoDox® in combination with ultrasound-guided High Intensity Focused Ultrasound (HIFU), in patients with metastatic liver cancer was initiated. The trial, which is supported by the National Institute for Health Research Oxford Biomedical Research Centre, will be carried out as a multi-disciplinary collaboration between Celsion, the Oxford University Institute of Biomedical Engineering, and the Oxford University Hospitals NHS Trust.

Announced \$1 Million NIH Grant for Glioblastoma Research with ThermoDox® and HIFU. In July, Celsion and Brigham and Women's Hospital, Harvard Medical School expanded their collaboration through the recent award of a \$1 million Career Development Grant from the National Institutes of Health's Center for Biomedical Imaging and Bioengineering (NIBIB). The grant will support preclinical studies evaluating ThermoDox® in combination with HIFU for the treatment of brain tumors.

Launched Commercialization of Reagent Products. In July, Celsion launched sales of its proprietary reagent products for life science research based on its newly acquired proprietary delivery platform technologies, TheraPlas™ and TheraSilence™, which are designed for optimal transfection (intra-cellular delivery) of plasmid DNA and RNA into human (and other mammalian) cells.

Financial Results

For the quarter ended June 30, 2014, Celsion reported a net loss of \$5.6 million net of acquisition costs compared to net income of \$421,000 in the same period of 2013. With \$1.1 million of acquisition costs, the net loss was \$6.7 million for the second quarter of 2014. Net income for the quarter ended June 30, 2013 was favorably impacted by lower operating costs (\$1.5 million) coupled with the non-cash benefit of \$4.4 million from the change in valuation of common stock warrant liability associated with equity financings in September 2009 and June 2013. In addition, the current quarter and six-month period ended June 30, 2014 included \$1.1 million of one-time costs associated with the acquisition of EGEN, Inc. in June 2014. For the six month period ended June 30, 2014, Celsion reported a net loss of \$12.1 million compared to a net loss of \$230,000 in the same prior year period. Net loss for the six months ended June 30, 2013 was favorably impacted by lower operating costs (\$1.9 million) coupled with the non-cash benefit of \$8.7 million from the change in valuation of common stock warrant liability associated with equity financings in September 2009 and June 2013. The Statement of Operations for the six month period ended June 30, 2013 was also impacted by a non-cash deemed dividend from the beneficial conversion feature of \$4.6 million on the preferred stock equity financing announced in February 2013, resulting in a net loss attributable to common shareholders for the six month period ended June 30, 2013 of \$4.8 million.

The Company ended the current quarter with \$50.1 million in cash, investments and accrued interest on short-term investments. Revenue from licensing collaborations totaled \$125,000 in each of the first two quarters of 2014 and 2013. Net cash used in operations was \$9.0 million for the six months ended June 30, 2014 compared to \$3.4 million in the same prior year period. This increase of \$5.6 million was due to a \$5 million payment from the Company's Chinese collaborator, Zhejiang Hisun Pharmaceutical Company, received in January 2013 for a non-refundable technology transfer fee. During the first six months of 2014, the Company raised approximately \$18.8 million in new capital, net of issuance costs, from the sale of stock to certain institutional investors in the first quarter and a second draw of \$5 million off its venture debt facility with Hercules Technology Growth Capital, Inc. in the second quarter.

Research and development (R&D) expenses increased by \$1.2 million from \$2.0 million in the second quarter of 2013 to \$3.2 million in the second quarter of 2014. R&D expenses increased by \$0.9 million from \$5.2 million in the six month period ended June 30, 2013 to \$6.1 million in the same period of 2014. The increase in R&D expenses was due primarily to start-up costs associated with Company's Phase III OPTIMA Study during the first half of 2014. General and administrative expenses were \$2.3 million in the second quarter of 2014 compared to \$2.0 million in the second quarter of 2013. General and administrative expenses were \$4.7 million in the first six months of 2014 compared to \$3.6 million in the comparable prior year period. These increases were primarily the result of higher insurance premiums and personnel costs (which includes an increase of \$0.9 million in non-cash stock option expense). The second quarter of 2014 included one-time costs of \$1.1 million for legal and banking fees and due diligence expenses associated with the June 2014 acquisition of EGEN, Inc.

Quarterly Conference Call

The Company is hosting a conference call to provide a business update and discuss the second quarter 2014 financial results at 11:00 a.m. EDT Thursday, August 7, 2014. To participate in the call, interested parties may dial 1-800-533-7954 (Toll-Free/North America) or 1-785-830-1924 (International/Toll) and ask for the Celsion Corporation Second Quarter 2014 Financial Results Conference Call (Conference Code: 8283269) approximately ten minutes before the call is scheduled to begin. The call will also be broadcast live on the internet at <http://www.celsion.com>.

The call will be archived for replay on Thursday, August 7, 2014 at 2:00 p.m. EDT and will remain available until Thursday, August 21, 2014. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 8283269. An audio replay of the call will also be available on the Company's website, <http://www.celsion.com>, for 30 days after 2:00 p.m. EST Thursday August 7, 2014.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. The pipeline also includes EGEN-001, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has three platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™ and TheraSilence™. For more information on Celsion, visit our website: <http://www.celsion.com>.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses or the possible failure to make such acquisitions or licenses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church
Senior Vice President and
Chief Financial Officer
609-482-2455
jchurch@celsion.com

Celsion Corporation
Condensed Statements of Operations
(In thousands except per share amounts)
(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2014	2013	2014	2013
Licensing revenue	\$ 125	\$ 125	\$ 250	\$ 250
Operating expenses:				
Research and development	3,166	2,022	6,059	5,226
General and administrative	2,305	1,951	4,739	3,639
Acquisition costs	1,067	—	1,067	—
Total operating expenses	<u>6,538</u>	<u>3,973</u>	<u>11,865</u>	<u>8,865</u>
Loss from operations	(6,413)	(3,848)	(11,615)	(8,615)
Other (expense) income:				
(Loss) gain from change in valuation of common stock warrant liability	(19)	4,380	(16)	8,660
Investment income, net	24	67	31	84
Interest expense	(263)	(176)	(494)	(357)
Other expense	(2)	(2)	(2)	(2)
Total other (expense) income, net	<u>(260)</u>	<u>4,269</u>	<u>(481)</u>	<u>8,385</u>
Net income (loss)	(6,673)	421	(12,096)	(230)
Non-cash deemed dividend from beneficial conversion feature on convertible preferred stock	—	—	—	(4,601)
Net (loss) income attributable to common shareholders	<u>\$ (6,673)</u>	<u>\$ 421</u>	<u>\$ (12,096)</u>	<u>\$ (4,831)</u>
Net income (loss) attributable to common shareholders per common share				
Basic and diluted	<u>\$ (0.38)</u>	<u>\$ 0.03</u>	<u>\$ (0.71)</u>	<u>\$ (0.45)</u>
Weighted average shares outstanding				
Basic	<u>17,527</u>	<u>12,087</u>	<u>16,932</u>	<u>10,807</u>
Diluted	<u>17,527</u>	<u>13,618</u>	<u>16,932</u>	<u>10,807</u>

Celsion Corporation
Selected Balance Sheet Information
(In thousands)

	June 30, 2014 (Unaudited)	December 31, 2013
ASSETS		
Current assets		
Cash and cash equivalents	\$ 9,598	\$ 5,719
Short term investments and accrued interest	40,462	37,368
Other current assets	486	675
Total current assets	<u>50,546</u>	<u>43,762</u>
Property and equipment	<u>851</u>	<u>833</u>
Other assets		
In-process research and development	25,802	–
Goodwill	1,939	–
Deposits, deferred fees and other assets	424	1,055
Patent license fees, net	16	21
Total other assets	<u>28,181</u>	<u>1,076</u>
Total assets	<u>\$ 79,578</u>	<u>\$ 45,671</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities	\$ 5,490	\$ 4,160
Notes payable – current portion	1,777	11
Deferred revenue – current portion	500	500
Total current liabilities	<u>7,767</u>	<u>4,671</u>
Earn-out milestone liability	13,878	–
Common stock warrant liability	495	3
Notes payable, net of discounts	7,868	5,000
Deferred revenue	3,750	4,000
Other non-current liabilities	461	473
Total liabilities	<u>34,219</u>	<u>14,147</u>
Stockholders' equity		
Preferred stock	–	–
Common stock	201	137
Additional paid-in capital	228,944	203,139
Accumulated other comprehensive loss	(12)	(44)
Accumulated deficit	(181,512)	(169,287)
Subtotal	<u>47,621</u>	<u>33,945</u>
Less: Treasury stock	(2,262)	(2,421)
Total stockholders' equity	<u>45,359</u>	<u>31,524</u>
Total liabilities and stockholders' equity	<u>\$ 79,578</u>	<u>\$ 45,671</u>